alnuctamab
bms
['bet', 'mmsm', 'equate', 'multiple myeloma', '#162', 'fil,veral,12', 'alnuctamab', '2019', 'cc-93269', 'bms', 'effector ', 'valent ,(-prevalent)']
alnuctamab 2+1 bcmaxcd3 t-cell engager: sq has better safety profile. orr 64% with high mrd negativity rates at the target dose #ash22 #mmsm 
MD PhD, Specialized in Multiple Myeloma. Memorial Sloan Kettering Cancer Center. Karolinska Institute. Tweets are my own.